The human endometrium is a dynamic tissue, which undergoes extensive tissue remodelling during the menstrual cycle. Due to their involvement in such processes, several well-characterized matrix metalloproteinases (MMP) have previously been studied in the endometrium. MMP-26 is a newly described matrilysin. We studied MMP-26 mRNA in 39 normal endometrial samples obtained across the menstrual cycle. Tissue distribution and cycle variation was examined using in-situ hybridization, Northern blot analyis and real time PCR. The probes for Northern blot analysis and real time PCR recognized non-overlapping sequences. MMP-26 was localized exclusively in epithelial cells of both glands and the luminal surface. Expression increased during the proliferative phase to a maximum at mid-cycle, then decreased to non-detectable levels in the late secretory and menstrual phases. Expression of MMP-26 mRNA in endometrial tissue explants in vitro required stimulation with both estradiol and progesterone. The tissue content of c-jun mRNA was assayed, since c-jun, as part of the enhancer complex AP-1, may be involved in regulation of MMP-26 gene transcription. The pattern of c-jun expression over the menstrual cycle was similar to that of MMP-26. Epithelial expression in the peri-and post-ovulatory stages of the menstrual cycle suggests the involvement of MMP-26 in reproductive processes.
Introduction
Matrix metalloproteinases (MMP) are zinc-dependent proteolytic enzymes involved in degradation of extracellular matrix (ECM) components such as collagen, proteoglycans, ®bronectin and laminin (Curry and Osteen, 2001) . The MMP and their tissue inhibitors (TIMP), together referred to as the MMP system, play important roles in a variety of physiological events, e.g. tissue repair, embryogenesis, extravillous trophoblast invasion and menstruation, as well as pathological processes, e.g. rheumatoid arthritis, atherosclerosis and tumour invasion (Nagase and Woessner, 1999) . The MMP family comprises >20 related proteolytic enzymes which are divided in subfamilies based on their domain structure. There are eight distinct structural classes of MMP, ®ve secreted and three membrane-type MMP (MT-MMP) (Egeblad, 2002) . With the exception of MT-MMP, which appear to be activated prior to their inclusion in the cell membrane, MMP are secreted as latent pro-enzymes which require subsequent proteolytic activation (Sternlicht and Werb, 2001) .
In normal ovulatory cycles, human endometrial tissue undergoes complex changes involving proliferation and subsequent differentiation of both epithelial and stromal components in preparation for embryo implantation. If no pregnancy occurs, the declining plasma levels of progesterone and estradiol initiate a cascade of events ultimately leading to breakdown and shedding of the functional layer of the endometrium as a menstrual bleeding. Disintegration in the late secretory phase of the endometrial basal lamina and cell-to-cell contacts in the stroma (Roberts et al., 1992) suggests that menstruation is preceded by degradation of ECM components Rodgers et al., 1994; Marbaix et al., 1995) .
MMP that are mainly or exclusively expressed in the peri-menstrual phase of the endometrial cycle include MMP-1 (Marbaix et al., 1995) , MMP-2 , MMP-3 (Hampton and Salamonsen, 1994) , MMP-7 (Rodgers et al., 1994) , MMP-9 (Rodgers et al., 1994) , MMP-10 (Rodgers et al., 1994) and MMP-11 . In contrast to MMP-7, which is predominantly found in epithelial cells (Rodgers et al., 1993; Wilson and Matrisian, 1996) , MMP-1 (Rawdanowicz et al., 1994) , MMP-2 (Rawdanowicz et al., 1994) , MMP-3 (Rawdanowicz et al., 1994) , MMP-9 (Rawdanowicz et al., 1994) , MMP-10 (Rodgers et al., 1994) and MMP-11 are expressed by stromal cells.
The cyclic pattern of endometrial expression of certain MMPs suggests regulation, direct or indirect, by gonadal steroids. In fact, physiological concentrations of progesterone almost totally suppress MMP-1 release (Lockwood et al., 1998) as well as MMP-2 and MMP-9 activity (Marbaix et al., 1992; Lockwood et al., 1998) in explant cultures of human endometrial tissue. Also, withdrawal of progesterone was followed by increased secretion of MMP-1, MMP-2, MMP-3 and MMP-9 by isolated stromal cells (Marbaix et al., 1992; Salamonsen et al., 1997) . In addition, cytokines such as interleukin1a (IL-1a), tumour necrosis factor-a (TNF-a) or transforming growth factor-b (TGF-b) released from adjacent cells in¯uence MMP expression under steroid control (Rawdanowicz et al., 1994; Bruner et al., 1995; Salamonsen and Woolley, 1996; Hulboy et al., 1997; Singer et al., 1997) .
Recently, four groups independently identi®ed the human gene encoding a novel metalloproteinase, MMP-26 (endometase; matrilysin-2) ( Marchenko et al., 2001) . This new member shares a number of structural and functional properties with matrilysin-1 (MMP-7) and has 52% amino acid identity with macrophage metalloelastase (MMP-12) (de Coignac et al., 2000) . MMP-26 is the smallest MMP identi®ed to date and its structure includes a signal sequence, a prodomain and a catalytic domain with the zinc-binding site. The gene is located on the short arm of chromosome 11 and encodes a 261 amino acid protein product.
Analysis of the proteolytic speci®city showed that MMP-26 is able to degrade a wide range of proteins present in the ECM and basement membrane such as ®bronectin, ®brinogen, vitronectin, a1-antitrypsin, a2-macroglobulin and denatured collagen (types I±IV). In addition, MMP-26 activates pro-MMP-9 in vitro (Uria, 2000) . In contrast, tenascin C, laminin V and native collagen (types I-IV) are resistant to proteolysis by MMP-26 (Marchenko et al., 2001) .
Tissue speci®c regulatory mechanisms have not yet been fully elucidated, but like many other MMP genes, the enhancer region of MMP-26 has a binding site for activator protein-1 (AP-1) (Marchenko et al., 2002) . AP-1, which stimulates transcription of a wide variety of genes involved in cell proliferation, apoptosis, survival and differentiation, is not a single protein, but a complex of proteins belonging to the Jun, Fos and ATF subfamilies (Shaulian and Karin, 2002) . Binding of AP-1 in the promoter region has been suggested to play an important role in transcriptional regulation of the MMP-26 gene (Marchenko et al., 2002) .
In this paper we report the epithelial location and the cyclic pattern of MMP-26 gene expression in human endometrium. By assaying c-jun mRNA we also explored the potential regulation of MMP-26 gene transcription by AP-1. Possible transcriptional effects of estradiol and progesterone were evaluated in endometrial tissue explants.
Materials and methods

Tissue sampling and processing
Endometrial tissue was collected from healthy women, aged 34±50 years, with regular menstrual cycles, between January 1996 and December 2001, at the Department of Gynecology and Obstetrics, Lund University Hospital. Tissue samples were obtained at diagnostic curettage or hysterectomy for benign reasons unrelated to endometrial dysfunction (e.g. leiomyoma, cervical dysplasia, uterine prolapse). Samples with endometrial pathology or samples from patients receiving steroid treatment were excluded from the study. All specimens were classi®ed according to an ideal 28 day reproductive cycle as early (n = 8), mid (n = 6) and late (n = 7) proliferative phase, early (n = 4), mid (n = 4) and late (n = 4) secretory phase, pre-menstrual (n = 3) and menstrual phase (n = 3) (Noyes, 1950; Hendrickson, 1980) . Early pregnancy decidua was obtained at legal abortion (n = 5) using vacuum aspiration. All samples were processed for both in-situ hybridization and Northern blot. Sampling was approved by the Review Board for studies in Human Subjects at the Lund University Hospital. All patients gave informed consent. Tissue samples were immediately frozen in dry ice in pieces (max. 4Q4Q4 mm) and stored at ±80°C until analysed. Tissue samples from ovary (n = 2), Fallopian tubes (n = 3), myometrium (n = 1), vagina (n = 1) and skeletal muscle (n = 2) were also obtained for comparison and frozen. Another set of endometrial tissue samples, to be used for explant cultures (n = 7), was transported to the laboratory in sterile phosphate-buffered saline (PBS).
mRNA extraction
One portion of each frozen sample was homogenized with a microdismembrator, weighed and RNA extracted for RNA using Trizol ReagentÔ (Life Technologies, Sweden). Frozen samples were homogenized in 1 ml of Trizol per 50 mg of tissue and centrifuged for 15 min at 12 000 g 4°C. After a 10 min incubation at room temperature, 0.2 ml of chloroform per 50 mg of tissue was added to the supernatant. Samples were vortex-mixed for 15 s and centrifuged for 15 min at 12 000 g at 4°C. Supernatant was mixed with isopropanol and salt solution (0.8 mol/l Na-citrate and 1.2 mol/l NaCl), 0.75 ml per 50 mg of tissue, and incubated at ±20°C for 60 min. After sedimentation, samples were centrifuged for 30 min at 12 000 g at 4°C. Supernatant was discarded and the pellet was dried with 75% ethanol, 1 ml per 50 mg of tissue. The RNA pellet was air-dried and diluted in RNase-free water. Total RNA was quanti®ed by measuring its absorbance in a spectrophotometer.
The other portion of each endometrial sample was processed for in-situ hybridization.
Preparation and labelling of cRNA probes
Single-stranded RNA probes were prepared from cloned MMP cDNA. For the human MMP-26 mRNA, a probe was used corresponding to 500 nucleotides (nt 225±725), GenBank accession AF248646 (Park et al., 2000) .
DNA templates were generated by PCR from the human MMP-26 cDNA using bipartite primers consisting of either a T7 RNA promoter and a downstream gene-speci®c sequence (anti-sense) or a T3 RNA promoter and an upstream gene-speci®c primer (sense). PCR reactions using 1 ng human MMP-26 cDNA, 1 mg primers, 200 mmol/l dNTP, 3 mmol/l MgCl 2 , 10 mmol/l Tris, pH 8.3, 50 mmol/l KCl, 2.5 IU Taq polymerase (Invitrogen) were ampli®ed at 95°C for 1 min, 62°C for 1 min and 72°C for 1 min for 30 cycles with a ®nal extension at 72°C for 10 min. The full-length size of transcripts was veri®ed with electrophoresis. DNA templates were puri®ed from agarose gels using QIAquick Gel Extraction Kit (250) (Qiagen). Complementary RNA (cRNA) probes were transcribed from 5 ng of gel-puri®ed DNA template using [ 35 S]UTP (1300 Ci/mmol; Dupont NEN) and either T3 or T7 RNA polymerase according to the manufacturer's instructions (Ambion MAXIscript) to generate sense and antisense probes respectively.
mRNA quanti®cation
Northern hybridizations
Electrophoretic separation of RNA and Northern transfers were performed according to standard procedures (Sambrook, 1989) . 10 mg of total RNA was separated on a 1% agarose, 0.66 mol/l formaldehyde gel using 1QMOPS running buffer and electrophoresing at 5 V/cm for 3 h. Gels were rinsed ®ve times in distilled water (5 min each rinse) and Northern transfer was set up using 10Qsaline sodium citrate (SSC) and Gene Screen Plus nylon membrane (Dupont). After overnight transfer, membranes were baked at 80°C for 2 h. Membranes were prehybridized for 2 h at 42°C in 10 ml ULTRAhyb (Ambion). cDNA probes were labelled using a Megaprime DNA labelling system (Amersham Pharmacia Biotech) and puri®ed using G-50 nick columns (Amersham Pharmacia Biotech). A probe was used corresponding to 500 nt (261±761), GenBank accession AF 248646 (Park et al., 2000) and hybridizations were performed overnight using pre-hybridization buffer containing 5Q10 5 cpm of denatured 32 P-labelled probe per ml. Membranes were washed twice in 2QSSPE, then twice in 0.1QSSPE, 0.1% sodium dodecyl sulphate (SDS), each wash at 42°C for 20 min. Washed membranes were exposed to a phosphor image plate (Fuji®lm) for between 4 and 20 h, then to Xray ®lm (Kodak) at ±80°C for between 1 and 7 days. Quanti®cation of transcripts following phosphor imaging was performed using ImageGauge software (Fuji®lm).
Real time PCR
A total of 20 ng of mRNA from each sample was reverse-transcribed using superscript II according to the manufacturer's manual (Invitrogen, USA). 2 ml of cDNA were ampli®ed by real time PCR with 1QTaqMan universal PCR mastermix (Applied Biosystems, USA). An MMP-26 Assay on Demand primer and probe kit was used (Hs002(2320 m1; Applied Biosystem). The TaqMan probe included the nucleotide region 122±146. For b-actin, 200 mmol/l of each primer and 1.25 pmol/l of probe were used and primers were designed using the Primer Express software (Applied Biosystems). b-actin was used as a housekeeping gene to normalize for RNA loading; the primers for b-actin were: b-actin-FW: 5-CTGGCTGCTGACCGAGG-3 and b-actin-RW: 5-GAAGGTCTCAAACATGATCTGGGT-3 and the probe was: b-actin-TM: 6FAM5¢-CCCTGAACCCCAAGGCCAACCG-3¢TAMRA. Each sample was analysed in duplicate using ABI prism 7000 (Applied Biosystems). The PCR ampli®cation was related to a standard curve.
mRNA localization
Cryostat sections 14 mm thick were collected on siliconized glass slides and subsequently stored at ±80°C until used for in-situ hybridization. Radiolabelled cRNA probe was transcribed from template using 20 mmol/l 35 [S]UTP (800 CI/ mmol). The RNA polymerases used were T3 for sense and T7 for antisense. Prior to hybridization, tissue sections were pre-treated as previously described (Young, 1990) . Sections were thawed directly in 4% formaldehyde in PBS and ®xed for 5 min, rinsed twice in PBS, and acetylated in 0.1 mol/l triethanolamine±HCl, 0.25% acetic anhydride, pH 8 for 10 min. Sections were then rinsed twice in 2QSSC, dehydrated in ethanol 70% for 1 min, 80% for 1 min, 95% for 2 min, 95% for 1 min, and 100% for 1 min, prior to air drying. cRNA hybridization histochemistry was performed as described by Cox et al. (1984) and Whit®eld et al. (1990) .
[ 35 S]cRNA probes were denatured at 65°C for 5 min and placed on ice for 5 min. Final hybridization buffer, with 1Q10 6 cpm of denatured [ 35 S]cRNA probe per 50 ml, consisted of 20 mmol/l Tris±HCl (pH 7.4), 1 mmol/l EDTA (pH 8.0), 300 mmol/l NaCl, 50% formamide, 10% dextrasulphate, 1QDenhardt's, 25 g/l yeast tRNA, 100 mg/l salmon sperm DNA, 250 mg/l total yeast RNA (fraction XI), 100 mmol/l dithiothreitol (DTT), 0.1% sodium thiosulphate, and 0.1% SDS.
Hybridization buffer (70 ml/15 cm 2 ) was applied to tissue sections on each slide and covered with untreated glass coverslips. Slides were then incubated at 56°C in chambers humidi®ed with 2QSSC with 50% formamide for 24 h. After hybridization, slides were cooled to room temperature, and coverslips werē oated off the slides in 4QSSC. Slides were then rinsed in four rounds of 4QSSC followed by immersion in 20 mg/l RNAse A at 37°C for 30 min. Sections were desalted in graded SSC solutions and washed twice in 0.1QSSC at 65°C for 30 min each. Sections were air-dried after dehydration in graded ethanol solutions. After hybridization, autoradiography with 1±4 days exposure to Kodak BioMax MR was performed. Slides were then coated with undiluted nuclear track emulsion (NTB-3, Kodak) and following exposure for 4±5 weeks at 4°C, slides were developed in D-19 (Kodak) and counterstained with 1% Toluidine Blue.
All slides were evaluated by two independent observers (R.P. and H.D). In order to allow semiquantitative evaluation, the intensity of the signal was graded as negative (±) when the signal was indistinguishable from the background; faint (+) when intensity was distinguishable from the background; moderate (++) when signal intensity was less than half maximal; strong (+++) when the signal was more than half maximal; very strong (++++) when the signal was maximal.
Explant cultures of intact endometrium
Fresh tissue was rinsed with Hanks' buffered salt solution (HBSS) and cut in 1 mm 3 pieces which were equally distributed in two 10 cm 2 tissue culture wells. Usually 4±6 pieces were cultured per well. Explant cultures were maintained in M199 (Life Technologies, USA) supplemented with 10% fetal bovine serum, 2 mmol/l glutamine, 100 000 IU/l penicillin, 100 mg/l streptomycin, and 0.25 mg/l fungizone and incubated in humidi®ed air with 5% CO 2 at 37°C (Casslen et al., 1995) . Phenol red was omitted from HBSS and M199 to avoid interference with the steroid receptors. Stock solutions of the hormones were made 1000 and 10 000 times their ®nal concentration, and the addition of ethanol was thereby kept at`0.1% in all experiments. One of the wells was treated with estradiol 10 ±8 mol/l and the other with estradiol 10 ±8 and progesterone 10 ±6 mol/l. The medium was replaced every second day with fresh medium together with hormones. After 5 days incubation, tissue samples were frozen at ±80°C and subsequently cryocut in 14 mm sections for in-situ hybridization.
Immunohistochemistry
Cryostat sections were ®xed in 4% buffered formalin for 15 min, and subsequently treated with 10 mmol/l citrate buffer pH 6.0 in a microwave oven at 550 W for 17 min, for antigen retrieval (Shi et al., 1991) . Immunostaining was performed in an automated immunostainer, TechMate 500 (Ventana Biotek, Tuscan, AZ, USA) using the biotin±streptavidin±peroxidase method with diaminobenzidine as the chromogen. Haematoxylin was used for counterstaining (Dako ChemMateÔ Detection Kit). The primary antibodies were monoclonals for the estrogen receptor (ER; Clone 1D5, DakoCytomation, Denmark) diluted 1:100 and the progesterone receptor (PR; Clone PR 636, DakoCytomation, USA) diluted 1:500. Immunostaining was evaluated by two independent observers (H.D. and R.P.) as semiquantitative estimates of the total nuclear intensity as 0, +, ++ or +++.
Statistical methods
Results are presented as mean and SEM. Mann±Whitney U-test was used to evaluate the signi®cance of differences between groups. Progressive variation during the menstrual cycle was evaluated with the test for trend. (Figure 1 ). The hybridization signal was evenly distributed in all glandular and luminal epithelial cells. No hybridization was detected in the stroma. Sections hybridized with the sense (control) probe had no signal.
Results
MMP-26 mRNA was found exclusively in epithelial cells in all positive specimens
Intensity of the hybridization signal was evaluated in all tissue sections using a semiquantitative scoring system (see Materials and methods). The signal increased gradually from early proliferative to early secretory phase, was lower in the mid-secretory phase and absent in the late secretory, pre-menstrual and menstrual phases (Figure 2 ). The decidual samples tested had no signal (data not shown).
MMP-26 mRNA isolated from the same endometrial sample was subjected to both Northern blot analysis and real time PCR ( Figure 2 ). The probes for Northern blot analysis and real time PCR recognized non-overlapping sequences. Peak expression was found in the early secretory phase and the transcript was virtually absent in the late secretory, pre-menstrual and menstrual phases. It appears that the mid secretory phase represents transition between high and low levels in the early versus late secretory phases, since two out of four samples were high whereas the other two were undetectable. RNA prepared from ovarian, tubal and skeletal muscle tissue were negative for MMP-26 mRNA. The amount of MMP-26 mRNA in preparations from vaginal and myometrial tissue was similar to that of early proliferative phase endometrium (data not shown). No MMP-26 mRNA was found in the decidual tissue of early pregnancy. . Endometrial samples were classi®ed as early (EP; n = 7), mid (MP; n = 6) and late (LP; n = 5) proliferative phase, early (ES; n = 4), mid (MS; n = 4) and late (LS; n = 4) secretory phase, pre-menstrual (PM; n = 3) and menstrual (M; n = 2) phase. The amount of MMP-26 mRNA was higher at mid-cycle (LP + ES) than in the early (P = 0.002) and late (P = 0.002) parts of the cycle. Endometrial samples were classi®ed as early (EP; n = 7), mid (MP; n = 6) and late (LP; n = 5) proliferative phase, early (ES; n = 4), mid (MS; n = 4) and late (LS; n = 4) secretory phase, pre-menstrual (PM; n = 3) and menstrual (M; n = 2) phase. The amount of MMP-26 mRNA was higher at mid-cycle (LP + ES) than in the early (P = 0.007) and late (P = 0.004) parts of the cycle.
Northern blot analysis of c-jun mRNA demonstrated a cyclic pattern with peak levels in the early and mid secretory phases (Figure 3 and Figure 6 ). RNA preparations from ovarian and tubal tissue were negative for c-jun mRNA, while the amount of c-jun mRNA in skeletal muscle, vaginal and myometrial tissue was similar to that in early proliferative endometrium (data not shown).
To test a possible steroid regulation of MMP-26 gene expression, endometrial explants were stimulated with estradiol alone or in combination with progesterone. Both ER and PR were detectable in all samples. In explants taken in the proliferative phase we found downregulation of PR, but not of ER, by progesterone. In contrast, the expression of ER and PR was not affected in secretory phase samples (data not shown). Proliferative phase explants treated with estradiol alone showed no hybridization signal, whereas those treated with the combination of estradiol and progesterone had a weak focal signal in epithelial but not in stromal cells. In contrast, explants obtained in the secretory phase did not express MMP-26 regardless of treatment conditions. Discussion MMP-26 has been identi®ed in epithelial cells in a variety of human tissues such as the uterus, placenta, kidney, brain, thymus and skeletal muscle (de Coignac et al., 2000; Park et al., 2000; Uria and LopezOtin, 2000) as well as in a variety of tumours of epithelial origin such as endometrial, lung and prostate cancer as well as choriocarcinoma (Uria and Lopez-Otin, 2000; Marchenko et al., 2001; Zhang et al., 2002) . In the present study of human endometrium we show that MMP-26 mRNA is exclusively expressed in epithelial cells, glandular as well as luminal, and is not detected in the stroma. Thus, our results support previous observations that MMP-26 is mainly epithelial, and these data together suggest a possible role for MMP-26 in the biology of normal as well as malignant epithelial cells.
Among MMP family members characterized so far, MMP-7 (matrilysin-1) (Rodgers et al., 1993; Wilson and Matrisian, 1996) and MMP-26 (matrilysin-2) are unique in their epithelial expression, which is in contrast to the stromal distribution of most other MMP (Rawdanowicz et al., 1994; Rodgers et al., 1994) . Classi®cation of these two MMP as matrilysins is based on similarities in substrate speci®city. Moreover MMP-26 shares minimal domain organization with MMP-7, including domains necessary for secretion, latency and catalytic activity. Based on such structural similarities between MMP-7 and MMP-26, the two matrilysins were proposed to constitute a distinct group in a domain-based classi®cation, as an alternative to the traditional substrate speci®city based classi®cation (Egeblad, 2002) .
Many MMP are reportedly expressed in endometrial tissue, but the cyclic pattern varies. We found the MMP-26 gene to be maximally expressed at mid-cycle, e.g. the late proliferative and early secretory phases. In contrast the expression of MMP-1 (interstitial collagenase), MMP-3 (stromelysin-1), MMP-7, MMP-9 (gelatinase-B), MMP-10 (stromelysin-2) and MMP-11 (stromelysin-3) are associated primarily with the menstrual period, with some of them found also in the proliferative phase Rodgers et al., 1994; Marbaix et al., 1995) . MMP-2 (gelatinase-A) is the only MMP that seems to be constitutively expressed in all phases of the endometrial cycle . Most MMP genes seem to be expressed when progesterone concentrations are low, i.e. during the menstrual and proliferative phases. Thus high progesterone levels in the secretory phase are associated with low expression of most MMP. However, results from some studies (Brenner et al., 1996; Salamonsen and Woolley, 1996) indicate that progesterone may not have a direct effect on MMP reduction during the secretory phase. In fact, MMP concentrations seem to drop before the rise of progesterone at the end of the proliferative phase.
Numerous cytokines are known to work in concert with progesterone to regulate MMP expression (Hulboy et al., 1997) . For example, the suppression of stromal-speci®c MMP-3 and epithelial-speci®c MMP-7 expression during the secretory phase of the menstrual cycle requires both progesterone and TGF-b Bruner et al., 1995) . In contrast to TGF-b that works cooperatively with progesterone to limit MMP expression, in¯ammatory cytokines, e.g. members of the IL-1 family, which are known to regulate MMP expression, may act in opposition to progesterone (Simon et al., 1994; Osteen et al., 1997) . For example, IL-1a released by endometrial epithelial cells is capable of stimulating MMP-3 expression in stromal cells. However, following progesterone exposure either in vivo or in vitro, MMP-3 expression in stromal cells becomes insensitive to cytokine stimulation Keller et al., 2000) . Furthermore, IL-1a expression appears to be linked to elevated levels of MMP-7 found in epithelial cells at sites of ectopic pregnancy . The expression pattern of MMP-26 suggests that IL-1a may contribute as a modulator.
TIMP-4 was recently suggested to be a physiological inhibitor of MMP-26 based on observations that it is a more potent inhibitor of MMP-26 than of MMP-1, -2, -3, -7 and -9 (Liu et al., 1997; Zhang et al., 2002) . However, to our knowledge, there are no data concerning endometrial expression of TIMP-4 and no studies of TIMP-4±MMP-26 interactions in endometrial tissue.
The two epithelial matrilysins MMP-7 and MMP-26 seem to be differentially regulated, since MMP-7 peaks in both the menstrual and the proliferative phase. The cyclical pattern of MMP-26 expression suggests steroidal regulation. Endometrial explants taken in the proliferative phase and cultured in the presence of estradiol and progesterone developed weak focal MMP-26 expression in glandular epithelial cells. No such expression was seen in explants treated with estradiol alone. This observation suggests that maximal expression requires progesterone stimulation of estrogen-primed endometrial tissue. The promoter region of MMP-26 lacks traditional progesterone- Figure 6 . c-jun mRNA and b-actin mRNA was quanti®ed in Northern blots of RNA extracted from endometrial tissue samples (n = 23). Endometrial samples were classi®ed as early (EP; n = 5), mid (MP; n = 4) and late (LP; n = 3) proliferative phase, early (ES; n = 2), mid (MS; n = 3) and late (LS; n = 2) secretory phase, pre-menstrual (PM; n = 3) and menstrual (M; n = 1) phase. The amount of c-jun mRNA increased from EP to MS (P = 0.04) and decreased from MS to M (P = 0.03).
response elements, suggesting that regulation may involve either additional enhancer elements further upstream, or an indirect effect via induction of as yet unknown intermediary proteins. In fact, cell±cell communication and stromal±epithelial contact appears to be crucial in the regulation of MMP expression following steroid exposure (Curry and Osteen, 2001) . Paracrine mediators such as growth factors, cytokines etc have been suggested (Hulboy et al., 1997) . In fact, proliferation of endometrial epithelial cells in response to estradiol is not direct but mediated via paracrine signals from the stroma (Cooke et al., 1998) .
Increasing levels of MMP-26 mRNA in endometrial tissue during the proliferative phase suggest stimulation by estradiol. However, we found up-regulation of MMP-26 mRNA by estradiol in endometrial tissue explants, and the promoter region does not include sequence homology with estrogen response elements. This makes a direct interaction of activated estrogen receptor with MMP-26 gene transcription less likely.
The promoter region of the MMP-26 gene contains an AP-1 site, and AP-1 function is critical for ef®ciency of the promoter (Marchenko et al., 2002) . In addition, cells transfected with the c-jun gene show up-regulated MMP-26 promoter activity (Marchenko et al., 2002) . The AP-1 transcription factor is composed of jun and fos (Shaulian and Karin, 2002) . We found c-jun expression to vary over the menstrual cycle with a mid-cycle maximum. This pattern was similar to that of MMP-26 expression. It is thus possible that c-jun expression is under steroid control, and that c-jun subsequently, as part of the AP-1 complex, takes part in the regulation of MMP-26 transcription. In fact, c-jun transcription is regulated by estradiol in the rat uterus (Nephew et al., 1994) . These data may suggest that c-jun, via AP-1, is under estrogen control and is involved in the regulation of endometrial MMP-26.
TCF-4 transcription factor, a crucial member of the APC±b-catenin±TCF pathway, has been described as a potent transcription regulator of MMP-26 in cancer cells of epithelial origin and the MMP-26 promoter has a TCF-4 site (Marchenko et al., 2002) . Since endometrial levels of E-cadherin, a-and b-catenin mRNA are lower in the proliferative than in the secretory phase (Fujimoto et al., 1996) , it appears less likely that TCF-4 stimulates MMP-26 gene transcription.
MMP-26 has the capability to activate pro-MMP-9 in vitro (Uria and Lopez-Otin, 2000) . Furthermore, MMP-9 is immunolocalized within luminal and glandular epithelium during the post-ovulatory period, with progression towards the apical surface of the cells and release of the enzyme into the uterine lumen at the time of implantation (Jeziorska et al., 1996) . The temporal and spatial expression suggests a role for MMP-26 and MMP-9 in the process of embryo implantation. During the invasive period of implantation, several barriers must be breached to establish functional connections to the blood supply for the conceptus. These barriers include the basement membrane of uterine epithelium, the interstitial matrix and the endothelium. In concordance with their speci®city, several MMP (e.g. MMP-2, MMP-9, MT1-MMP), which are expressed in the secretory phase, were suggested to play a role during implantation (Salamonsen and Nie, 2002) . A recent study found MMP-26 in the uterine glands of rhesus monkeys with maximal expression during the ®rst few days after implantation, and suggested a role for this enzyme during the implantation process (Li et al., 2002) . Since no data are available from early human implantation sites, all information is obtained from examination of MMP expression in endometrium during the secretory phase of the menstrual cycle and in decidual tissue derived from abortions during the ®rst trimester. We found no expression of MMP-26 in early pregnancy decidua. However, these samples were obtained no earlier than 4 weeks after implantation. This agrees with the ®nding of was not expressed in the decidua at 26 days after implantation. MMP-26 may play a role during the process of implantation, either directly or as an activator of pro-MMP-9, or as a possible regulator of bioavailability of other molecules such as cytokines, growth factors and vasoactive factors.
